Abstract: A transdermal therapeutic system containing the active substance 17-.beta.-estradiol and optionally further active substances has a laminated structure positioned on a backing layer which is essentially impermeable to active substance and moisture, at least one matrix layer and optionally an adhesive layer. The at least one matrix layer or the adhesive layer contains anhydrous 17-.beta.-estradiol in crystalline form.

Abstract: Transdermal therapeutic system comprising the active substance acetylsalicylic acid, having a layered structure consisting of a backing layer which is substantially impermeable to active substances and moisture and one or several active substance-containing matrix layers, which is characterized in that at least one of said matrix layers comprises acetylsalicylic acid in mainly crystalline form.

Abstract: A transdermal therapeutic system exhibiting layered structure consists of a backing layer which is impermeable to active substances, a matrix having water-insoluble basic material and islands (inclusions) divided therein, and a layer controlling the access of cutaneous liquid by means of which the matrix is activatable. Process for the production are described.

Abstract: A transdermal therapeutic system which is composed of layers exhibits an electrically insulating backing layer (1) being impermeable to active substances, and two galvanic elements which are positioned in separation from each other. The skin-facing electrodes of the galvanic elements have layers thereon consisting of a liquid absorbing material becoming ionically conductive after liquid admission. The layer of at least one of the dermad electrodes comprises a pharmaceutical active substance.

Abstract: A presentation which, in the form of a film, permits the individual dosage of drugs, confectionary, other food, cosmetics and the like for oral application or intake. The presentation is characterized by the fact that it comprises a mass of 20 to 60%-wt. of at least a film former, 2 to 40%-wt. of at least a gel former, 0.1 to 35%-wt. of at least an active substance, and up to 40%-wt. of an inert filling agent, being applied on a carrier, or by consisting of a mass having the aforementioned composition but is unsupported. In the production thereof, an intimate mixture of said components is prepared, optionally with the addition of up to 30%-wt. of a polar solvent, and processed to form a homogeneous, spreadable or extrudable mass.

Abstract: The present invention relates to a transdermal therapeutic system with tulobuterol or one of the pharmaceutically acceptable salts thereof as active substance, comprising a backing layer which is substantially impermeable to active substances and at least one matrix layer which contains the active substance, which matrix layer comprises at least one styrene-1,3-diene-styrene block copolymer. The present invention is further directed to a process for the production of said transdermal therapeutic system.

Abstract: A transdermal therapeutic system exhibiting layered structure consists of a backing layer which is impermeable to active substances, a matrix having water-insoluble basic material and islands (inclusions) divided therein, and a layer controlling the access of cutaneous liquid by means of which the matrix is activatable. Process for the production are described.

Abstract: Transdermal therapeutic system for administration of moxonidine, containing at least one higher n-alkane-carboxylic acid with at least 12 C atoms as a permeation accelerator.